source
- Fugitive Discovered Working Under Alias in Biotech Industry Amid Legal Battles Involving AstraZeneca and LillyA Rhode Island fugitive who had been on the most-wanted list was recently uncovered as having worked under a false identity in the biotech sector. The revelation raised questions about how the ind…
- STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drugSTAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.